Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease (DISCHARGE)

Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies) - A Pragmatic Randomised Controlled Trial of CT Versus ICA

The primary hypothesis is that computed tomography (CT) is superior to invasive coronary angiography (ICA) concerning the primary endpoint MACE (MACE = major adverse cardiovascular event; defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) after a maximum follow-up of 4 years, in other words, that CT will result in a significantly lower rate of MACE. Secondary outcomes include MICE (MICE = minor cardiovascular events), procedural complications, cost-effectiveness, radiation exposure, cross-over to CT or ICA, gender differences, and health-related quality of life.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Procedure: Computed tomography angiography (cardiac CT); Procedure: Invasive coronary angiography (ICA)

Detailed Description

The primary objective of this prospective pragmatic randomised controlled trial (PRCT) in 3546 patients is to evaluate the possible superiority of a CT-based patient management over an ICA-based management strategy in stable chest pain patients with intermediate pretest probability (10-60%) of coronary artery disease. The primary outcome measure is the occurrence of MACE (MACE = major adverse cardiovascular events; defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) after a maximum follow-up of 4 years after CT or ICA. Secondary outcomes include health related quality of life, cost-effectiveness, cross-over to ICA/CT. Procedural complications are classified into major and minor. Major procedural complications are a composite end-point and include death, nonfatal stroke, nonfatal myocardial infarction, and further complications prolonging hospitalization by at least 24 hrs,as well as dissection (coronary, aorta), cardiogenic shock, cardiac tamponade, retroperitoneal bleeding, cardiac arrhythmia (ventricular tachycardia, ventricular fibrillation), cardiac arrest. Possible minor procedural complications: Hematoma at the puncture site, secondary bleeding at the puncture site, bradycardia, angina without infarction, allergoid contrast agent reaction, stent migration, hypotension requiring treatment, headache, hyperthyreodism, skin tissue and nerve injuries, extravasate, cardiac arrhythmia, contrast-induced nephropathy (CIN), infections, femoral arterial occlusion (or arterial access vessel) or dissection, new requirement for dialysis, DVT/pulmonary embolism, closure or injury of vessels, injury of the heart (e.g. valve or myocardium), , perforation, gastrointestinal bleeding, genital-urinary bleeding, other major bleeding, red blood cell (RBC)/whole blood transfusion, twisting or rupture of the catheter part, other equipment mishaps (e.g. retained foreign body guidewire fracture), development of arterio-venous fistula(s), development of pseudo aneurysm at puncture site, dissection (except coronary dissection), permanent edema (e.g. due to lymphatic congestion at puncture site), embolisation of central or peripheral vessels due to thromboembolis, acute closure of coronary vessels, stent infection, heart failure, wrong patient or wrong procedure and other.

This study is a European multicentre study conducted at 26 clinical centres in 16 European countries and is methodologically based on the single-centre CAD-Man trial conducted by Charité (NCT00844220). The pragmatic approach of the study ensures generating practical and usable outcomes for clinical decision-making according to comparative effectiveness research methodology.

In a preceding pilot study, data for cost-effectiveness analyses and image-quality analyses are collected and methods are defined for implementation in the main PRCT. Also appropriate instruments for health related quality of life are being chosen.

DISCHARGE receives funding from the 7th Framework Programme of the European Commission (EC-GA 603266).

• Study Type: Interventional
• Enrollment (Estimated): 3546
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Austria
  • Innsbruck, Austria, 6020
    • Medizinische Universitaet Innsbruck
• Czechia
  • Prague, Czechia, 15006
    • Fakultni nemocnice v Motole
• Denmark
  • Copenhagen, Denmark, 3400
    • Region Hovedstaden
• Germany
  • Berlin, Germany, 10117
    • Charite - Universitatsmedizin Berlin
  • Göppingen, Germany, 73035
    • Alb Fils Kliniken GmbH
  • Leipzig, Germany, 04109
    • Universitaet Leipzig
• Hungary
  • Budapest, Hungary, 1085
    • Semmelweis Egyetem
• Ireland
  • Dublin, Ireland, 4
    • University College Dublin, National University of Ireland
• Italy
  • Cagliari, Italy, 09124
    • Università degli Studi di Cagliari
  • Rome, Italy, 00185
    • Università degli Studi di Roma La Sapienza
• Latvia
  • Riga, Latvia, 1002
    • Paula Stradina Kliniska Universitates Slimnica As
• Lithuania
  • Kaunas, Lithuania, 44307
    • Lietuvos sveikatos mokslų universitetas
• Poland
  • Wroclaw, Poland, 51124
    • Wojewodzki Szpital Specjalistyczny we Wroclawiu
• Portugal
  • Vila Nova de Gaia, Portugal, 4434502
    • Centro Hospitalar de Vila Nova de Gaia/Espinho EPE
• Romania
  • Targu Mures, Romania, 540124
    • Cardio Med SRL
• Serbia
  • Novi Sad, Serbia, 21204
    • Institut Za Kardiovaskularne Bolesti Vojvodine
• Spain
  • Barcelona, Spain, 08007
    • Institut Català de la Salut
• United Kingdom
  • Belfast, United Kingdom, BT16 1RH
    • South Eastern Health and Social Care Trust Nhs
  • Glasgow, United Kingdom, G12 8QQ
    • University of Glasgow
  • Liverpool, United Kingdom, L9 7AL
    • Aintree University Hospital NHS Foundation Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with suspected coronary artery disease with stable chest pain and intermediate pretest probability (10-60%) of CAD referred for conventional coronary angiography.

"Stable chest pain" defined as not:

• being acute (= first appearance within the last 48 hours) or
• instable (= a) first appearance with at least Canadian Cardiovascular Society Angina Grading Scale (CCS) Class III, b) progredient with at least 1 CCS Class to at least CCS Class III or, now at rest for at least 20 min) angina pectoris
• Patients at least 30 years of age
• Written informed consent

Exclusion Criteria:

• Patients on hemodialysis
• No sinus rhythm
• Pregnancy
• Any medical condition that leads to the concern that participation is not in the best interest of health (e.g., extensive comorbidities)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Computed Tomography Angiography (CTA); Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography	Procedure: Computed tomography angiography (cardiac CT); Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
Active Comparator: Invasive coronary angiography (ICA); Invasive coronary angiography	Procedure: Invasive coronary angiography (ICA); Clinical management/treatment decisions based on invasive coronary angiography

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major Adverse Cardiovascular Event	Composite endpoint: major adverse cardiovascular event (MACE); defined as at least one of the following: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.	1 minute after randomisation to CT/ICA diagnostic procedure and during follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Likelihood of receiving coronary intervention in different European countries	Likelihood of receiving coronary intervention and extent of Coronary Artery Disease (CAD) in dependence of socioeconomic status and the likelihood of receiving further intervention within two months after the initial intervention in different European countries.	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
Rates of percutaneous coronary intervention and use of intracoronary techniques different European countries	Composite outcome: Rates of Percutaneous Coronary Intervention (PCI) and use of intracoronary techniques such as Fractional Flow Reserve (FFR), Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS) within two months after the initial intervention in different European countries.	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
Patient management in different European countries	Recommended and actually performed management based on Computed Tomographic Angiography (CTA) and Invasive Coronary Angiography (ICA) results in different countries adjusted for the extent of ischemia within two month after the initial test randomised to.	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
Follow-up strategies in different European countries	Composite outcome: Adherence to follow-up in different countries and according to prevalence of CAD as well as risk factors and socioeconomic status and most likely way of conduct of follow-up data gathering in different countries (phone interviews, letter reply, email).	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
European differences in occurrence and extent of Coronary Artery Disease in regards to city versus rural lifestyle	European differences in occurrence and extent of Coronary Artery Disease in regards to city versus rural lifestyle	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
European and local differences in patient consent of sites	European and local differences in patient consent of sites	at baseline, 1-year follow-up and final follow-up up to a max of 4 years
Comparison in the Coronary Computed Tomographic Angiography and Invasive Coronary Angiography group:Occurrence of Minor Adverse Cardiovascular Events	Occurrence of minor adverse cardiovascular events (MICE): coronary revascularisation, peripheral artery revascularisation, hospitalisation for angina pectoris, emergency department visit for angina pectoris, transient ischemic attack, congestive heart failure.	1 minute after randomisation to CT/ICA diagnostic procedure and during follow-up
Comparison in the Computed Tomography Angiography and Invasive coronary Angiography group: Percutaneous Coronary Intervention and Coronary Artery Bypass Graft	Composite outcome: Rates of Percutaneous Coronary Intervention and Coronary Artery Bypass Graft (CABG) performed within 2 months following Computed Tomography Angiography and Invasive Coronary Angiography (defined as: related to these tests) and more than 2 months after CTA and ICA until follow-up (unrelated to these tests).	during the CTA/ICA examination, up to 48h after hours after the final procedure related to the test randomized to, 1-year follow-up and final follow-up to a max of 4 years
Comparison in the Computer Tomography Angiography and Invasive Coronary Angiography group: Rates of patients on dialysis	Comparison in the CTA and ICA group: Rates of patients on dialysis	during the CTA /ICA examination, up to 48h after hours after the final procedure related to the test randomized to, 1-year follow-up and final follow-up to a max of 4 years
Comparison in the Computer Tomography Angiography and Invasive Coronary Angiography group: Rate of coronary anatomical anomalies	Composite outcome: Rate of coronary artery anomalies (benign and malignant) and rate of myocardial bridging seen on CTA and ICA and the clinical implications of these at follow-up as well as influence on Major Adverse Cardiovascular Events (MACE) and MICE	during the CTA /ICA examination, up to 48h after hours after the final procedure related to the test randomized to, 1-year follow-up and final follow-up to a max of 4 years
Comparison in the computer tomography angiography and invasive coronary angiography group: Rates of patients undergoing further cardiac diagnostics	Composite outcome: Rates of patients undergoing further cardiac diagnostics, such as additional CT or ICA, Electrocardiography (ECG), Exercise ECG, Echo, Stress Echo, Magnetic Resonance Imaging (MRI) within 2 months following CT and invasive coronary angiography (defined as: related to these tests) and more than 2 months after CT and invasive coronary angiography until follow-up (unrelated to these tests).	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Comparison in the computer tomography angiography and invasive coronary angiography group: Rates of coronary interventions	Rates of coronary interventions within 2 months following CT and ICA (defined as: related to these tests) and more than 2 months after CT and ICA until follow-up and recurrent angina leading to hospitalisation.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Analysis of the influence of prior computer tomography angiography on invasive coronary angiography and percutaneous coronary intervention	Analysis of influence of prior CT on ICA and PCI in terms of duration, radiation exposure, amount of contrast agent used for ICA.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Comparison of cumulative contrast agent amount in the two arms	Comparison of cumulative contrast agent amount in the two arms	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Comparison in the computer tomography angiography and invasive coronary angiography group: Number/proportion of patients undergoing coronary revascularization	Composite outcome: Compared with ICA, CTA will be associated with a lower rate of coronary revascularisation, but on a per-procedure basis, revascularisation will be more complete. Performance of revascularisation will differ between the randomised groups.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Comparison in the computer tomography angiography and invasive coronary angiography group: Distribution in the mode of revascularization: percutaneous coronary intervention vs. coronary artery bypass graft	Comparison in the CTA and ICA group: Distribution in the mode of revascularisation: PCI vs. CABG.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow up to a max of 4 years
Comparison of Quality of Life between treatment regimens.	Comparison of Quality of Life between the following treatment regimens using adherence to therapy recommendation as covariate: optimal medical therapy in general in combination with risk factor modification vs. oral statin intake in combination with risk factor modification.	at 1-year follow-up and final follow-up to a max of 4 years
Geographical distribution of risk factors for Major Cardiovascular Events and Minor Cardiovascular Events and other events	Geographical distribution of risk factors for MACE and MICE, cardiovascular events and cardiac events (cardiac and non-cardiac death, stroke, myocardial infarction, unstable angina pectoris, re-revascularisation and first revascularisation) in the European Union (EU) and comparison of European countries.	at 1-year follow-up and final follow-up to a max of 4 years
Extent of Coronary Artery Disease	Extent of CAD in dependence of patients' socioeconomic status (income, education, occupation, job situation, gender)	at 1-year follow-up and final follow-up to a max of 4 years
Time from randomisation to Invasive Coronary Angiography in both groups	Time from randomisation to Invasive Coronary Angiography in both groups.	at 1-year follow-up and final follow-up to a max of 4 years
Time from randomisation to first coronary revascularisation in both groups	Time from randomisation to first coronary revascularisation in both groups	at 1-year follow-up and final follow-up to a max of 4 years
Completeness of revascularisation for Percutaneous Coronary Intervention single vessel vs multivessel Percutaneous Coronary Intervention and Coronary Artery Bypass Graft; stent use (bare metal vs drug eluting)	Completeness of revascularisation (i.e. no. of vessels treated vs. number of vessels affected by > 50% stenosis); for Percutaneous Coronary Intervention single vessel vs multivessel Percutaneous Coronary Intervention and Coronary Artery Bypass Graft; stent use (bare metal vs drug eluting).	at 1-year follow-up and final follow-up to a max of 4 years
Information on surgical procedures i.e. isolated Coronary Artery Bypass Graft, Coronary Artery Bypass graft with valve replacement, Coronary Artery Bypass Graft with aortic surgery	Information on surgical procedures i.e. isolated Coronary Artery Bypass Graft, Coronary Artery Bypass graft with valve replacement, Coronary Artery Bypass Graft with aortic surgery.	at 1-year follow-up and final follow-up to a max of 4 years
Comparison in the Computer Tomography Angiography and Invasive Coronary Angiography group: procedures and outcomes in relation to age	Comparison in the Computer Tomography angiography and Invasive Coronary Angiography group: procedures and outcomes in relation to age.	at 1-year follow-up and final follow-up to a max of 4 years
Comparison in the Computer Tomography Angiography and Invasive Coronary Angiography group: procedures and outcomes in relation to body mass index and obesity	Comparison in the Computer Tomography Angiography and Invasive Coronary Angiography group: procedures and outcomes in relation to body mass index and obesity.	at 1-year follow-up and final follow-up to a max of 4 years
Reduction of angina pectoris intensity	Composite outcome: Reduction of angina pectoris intensity (measured on a 0-10 scale, at baseline, first and final follow up, max 4 years) in the two arms and in the subgroup of a) patients with significant stenosis (on CTA or ICA) and with or without relevant myocardial ischemia that was or was not revascularised by PCI or CABG; b) patients without significant stenosis (on CT or ICA) and with or without non-coronary or non-cardiac finding potentially explaining the chest discomfort; in patients who underwent PCI versus patients who received optimal medical therapy and risk factor modification alone (matched analysis for the extent of CAD and imaging ischemia).	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Validation of different questionnaires to predict Major and Minor Adverse Cardiac Events	Composite outcome: Validation of the Rose Angina questionnaire including pain scale and the InterHeart Risk Score (IHRS) to predict MACE and MICE in both arms.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Occurrence of adverse events due to medication	Composite outcome: Adverse events due to nitroglycerin, beta-blockers, contrast agent and other medication applied during CTA and ICA (allergic reactions, hypotension, headache, hyperthyroidism).	during the procedure or within 48 hours post last related procedure
Occurrence of adverse events related to venous or arterial puncture	Composite outcome: Adverse events related to venous or arterial puncture: skin tissue and nerve injuries, bleedings: due to puncture of vessel, due to use of anticoagulants, at site of puncture (hematoma), extravasate.	during the procedure or within 48 hours post last related procedure
Occurrence of cardiac arrhythmia	Occurrence of cardiac arrhythmia	during the procedure or within 48 hours post last related procedure
Rates of contrast-induced nephropathy	Rates of contrast-induced nephropathy (CIN) adjusted for the frequency of creatinine follow-up testing performed in the two groups.	up to 48h after hours after the final procedure related to the test randomised to
Infections	Infections	during the procedure or within 48 hours post last related procedure
Influence of experience of examiners on events	Correlation of the experience (in years) of the CT and ICA examiner with procedural events, duration of the exams (in min), contrast agent amount (in ml) used for diagnosis and intervention (if done), and exposure of radiation (in mSv).	during the procedure or within 48 hours post last related procedure
Comparison of occurrence of procedural complications related to Invasive Coronary Angiography	Composite outcome: Comparison of a) outpatient vs inpatient ICA for procedural complication rates after adjusting for risk factors for such events,b) femoral vs radial approach ICA, and c) different closure devices vs. manual compression and of frequency of interventions, results, patients acceptance and d) procedural differences, for instance bed rest time after intervention, and influence on procedural events.	during the procedure or within 48 hours post last related procedure
Procedural complications related to Invasive Coronary Angiography	Composite outcome: Complications related to ICA: Femoral arterial occlusion (or arterial access vessel) or dissection, Cardiac arrhythmia, closure or injury of vessels, injury of the heart (e.g. valve or myocardium) , twisting or rupture of the catheter or parts of the catheter consecutive surgical removal, development of arteria-venous fistulas, development of a pseudo aneurysm at puncture site, permanent edemas, embolisation of central or peripheral vessels due to thromboembolism.	during the procedure or within 48 hours post last related procedure
Procedural complications during or after revascularisation	Complications during or after revascularisation, for instance acute closure of coronary vessels, angina pectoris, stent migration, loss of stent and consecutive closure of vessels, stent infection.	during the procedure or within 48 hours post last related procedure
Occurrence of other adverse events and serious adverse events in the Invasive Coronary Angiography group	Composite outcome: Occurrence of other adverse events (AEs) and serious adverse events (SAEs) such as heart failure, cardiogenic shock, cerebrovascular accident (CVA)/Stroke, hemorrhagic stroke, new requirement for dialysis, deep vein thrombosis/pulmonary embolism, cardiac tamponade, perforation, retroperitoneal bleeding, gastrointestinal bleeding, genital-urinary bleeding, major bleeding, red blood cell (RBC)/Whole blood transfusion, other equipment mishaps (e.g. retained foreign body guidewire fracture), wrong patient or wrong procedure	during the procedure or within 48 hours post last related procedure
Comparison of incidental findings in Computed Tomography Angiography and Invasive Coronary Angiography group and potential benefits and harms of findings Analysis of prevalence non-coronary cardiac and non-cardiac causes of symptoms	Analysis of prevalence of a) non-coronary cardiac causes of symptoms (such as aortic dissection, valve disease, pericarditis) or b) non-cardiac causes of symptoms (such as thrombus, pulmonary embolism, pleural effusion, pneumonia, hiatal hernia).	during CTA and ICA examination, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a max of 4 years
Comparison of incidental findings in both arms and potential benefits and harms of findings:Influence of non-coronary cardiac and non-cardiac findings on Major Adverse Cardiac Events, non-cardiac events and Quality of Life	Influence of non-coronary cardiac and non-cardiac findings on MACE, non-cardiac events and Quality of Life (QoL).	during CTA and ICA examination, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a max of 4 years
Comparison of incidental findings in Computed Tomography Angiography and Invasive Coronary Angiography group and potential benefits and harms of findings: Rate for malignancy in nodules seen on Computed Tomography Angiography	Rate for malignancy in nodules seen on CT (reference standard: biopsy results, Positron Emission Tomography (PET) findings, or progression versus no change or regression on follow-up CT.	during CTA and ICA examination, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a max of 4 years
Comparison of incidental findings in Computed Tomography Angiography and Invasive Coronary Angiography group and potential benefits and harms of findings	Accuracy of the parsimonious lung cancer risk prediction tool by McWilliams et al. for probability assessment of malignancy in lung nodules found in comparison to the above combined reference standard	during CTA and ICA examination, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a max of 4 years
Comparison of incidental findings in Computed Tomography Angiography and Invasive Coronary Angiography group and potential benefits and harms of findings: Rate of death from cancer in both groups	Rate of death from cancer in both groups	at 1-year follow-up and final follow-up to a maximum of 4 years
Comparison of incidental findings in Computed Tomography Angiography and Invasive Coronary Angiography group and potential benefits and harms of findings:Rates of unnecessary follow-up procedures	Composite outcome: Rates of unnecessary follow-up procedures such as examinations, biopsies, or surgeries done based on non-coronary findings in the CTA and ICA group	at 1-year follow-up and final follow-up to a maximum of 4 years
Analysis of interobserver variability (site versus core lab)	Analysis of interobserver variability (site vs. core lab) of reading for coronary stenosis and plaques on CTA and for coronary stenosis on ICA	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Percent diameter stenosis correlation and agreement by both diagnostic tests in patients who underwent Invasive Coronary Angiography in the Computed Tomography Angiography group after positive or non-diagnostic findings	Percent diameter stenosis correlation and agreement by Computed Tomography Angiography and Invasive Coronary Angiography in patients who underwent Invasive Coronary Angiography in the Computed Tomography Angiography group after positive or non-diagnostic findings.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Non-diagnostic Computed Tomography Angiography and Invasive Coronary Angiography	Composite outcome: Non-diagnostic CTA and ICA: comparison of prevalence and patient as well as technical factors leading to such uninterpretable findings or exams that could not be conducted or completed.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation between percent diameter stenosis	Correlation between percent diameter stenosis by Computed Tomography with invasive Fractional Flow Reserve in patients who had Computed Tomography and Invasive Coronary Angiography done and correlation of non-invasively estimated Fractional Flow Reserve by Computed Tomography with invasive Fractional Flow Reserve after Computed Tomography/Invasive Coronary Angiography.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Prevalence of sinus node artery being a side branch of Left Coronary Artery or Right Coronary Artery	Prevalence of sinus node artery being a side branch of Left Coronary Artery (LCX) or Right Coronary Artery RCA by core lab reading and the risk of CAD on CT and ICA as well as MICE and MACE.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Prevalence of left, intermediate, and right coronary distribution type	Prevalence of left, intermediate, and right coronary distribution type by core lab and site reading and the risk of CAD (as significant) on CT and ICA at baseline and MICE and MACE.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Improvement of selection of distal coronary segments used for CABG-anastomosis by CT in comparison to ICA alone (especially heavy calcification detection) as assessed by the cardiac surgeons.	Improvement of selection of distal coronary segments used for Coronary Artery Bypass Surgery-anastomosis by Computed Tomography in comparison to Invasive Coronary Angiography alone (especially heavy calcification detection) as assessed by the cardiac surgeons.	at 1-year follow-up and final follow-up to a maximum of 4 years
Relation of plaque characterisation and quantification by core lab and Major and Minor Adverse Cardiac Events at the two follow-up results	Relation of plaque characterisation and quantification by core lab and MACE and MICE at the two follow-up results.	at 1-year follow-up and final follow-up to a maximum of 4 years
Image quality of Computed Tomography by core lab read and flow and concentration of contrast agent used intravenously	Image quality of CT by core lab read and flow and concentration of contrast agent used intravenously	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Coronary artery dimensions	Coronary artery dimensions in patients in whom contraindications prevented the use of nitroglycerin for CTA versus patients who received nitroglycerin (measured as the diameter of the Left Marginal Artery (LMA), proximal Left Anterior descending artery (LAD), LCX and RCA), adjusted for gender and Body Surface Area (BSA).	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Noise in Computed Tomography Angiography imaging	Noise in CTA imaging and the factors it depends on for instance adherence vs non-adherence to scan protocol.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Factors that influence the image quality of Computed Tomography Angiography	Factors that influence the image quality of CTA ( Body Mass Index (BMI), gender, origin of patient, 80, 100, 120, 135, 140 kV, different mA settings, number of detector rows, heart rate (maximum, minimum, and average during CT acquisition), and acquisition type.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Accuracy and agreement of RCADIA system		during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
10-step Guide to cardiac CT	Evaluation of the 10-step guide to cardiac CT	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Semi-qualitative analysis	Composite outcome: intensity, noise, signal to noise, contrast and signal to noise in some regions of interest (ROIs) (LV, RV segments 1,2,5,6,11 and levocardiography effect).	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Qualitative analysis	Composite outcome: levocardiography effect (scale 1 to 3) and LV, RV and segments 1,2,5,6,11 (scale 1 to 4).	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Heart rate reduction achieved in Computed Tomography by the DISCHARGE betablocker protocol	Heart rate reduction achieved in Computed Tomography by the DISCHARGE betablocker protocol	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Heart rate reduction achieved in subgroups	Composite outcome: Heart rate reduction achieved in subgroups of patients with contraindication to betablockers or no adherence to protocol where other doses or medications such as ivabradine or calcium channel blockers were used and in different patient groups (e.g., male versus female patients, >65 years and up to 65 years of age).	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Heart rate reduction achieved with conscious sedation, if used, for Computed Tomography	Heart rate reduction achieved with conscious sedation, if used, for CT.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Correlation of extent of Coronary Artery Disease and a high calcium score	Composite outcome: Analysis of prevalence and extent of CAD in correlation to a high calcium score (CS), and exclusion of any CAD in correlation to a zero CS, potential of defining a threshold.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Characterisation of plaques	The characterisation of plaques (type and composition) by CT core lab in relation to cardiac risk factors.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Differences in plaque characteristics	Composite outcome: Differences in plaque characteristics (type and composition) and analysis of potential influence by geographical origin of the patient, after adjustment for other cardiac risk factors.	during the Computed Tomography examination and up to 6 months after the Pragmatic Randomised Controlled Trial
Comparison of Computed Tomography Angiography and intracoronary techniques	Composite outcome: Correlation and agreement for plaque characterisation and quantification by CT in comparison to intracoronary techniques such as OCT and Intravascular ultrasound (IVUS) in patients who had both tests done.	during the Computed Tomography examination and up to 6 months after the pragmatic Randomised Controlled Trial
Influence of statin treatment on plaque development	Risk factors for and influence of statin treatment on plaque progression or regression in patients who had follow-up cardiac CT done in the CT group.	during the Computed Tomography examination and up to 6 months after the pragmatic Randomised Controlled Trial
Correlation of effective dose and the diagnostic portion of Invasive Coronary Angiography with weight and body-mass index of the patient.	Correlation of effective dose and the diagnostic portion of Invasive Coronary Angiography with weight and body-mass index of the patient.	during the Invasive Coronary Angiography examination, at 1-year follow-up and at final follow-up to a maximum of 4 years
Correlation of effective dose of and contrast agent amount used for Invasive Coronary Angiography with severity of Coronary Artery Disease	Correlation of effective dose of and contrast agent amount used for Invasive Coronary Angiography with severity of Coronary Artery Disease.	during the Invasive Coronary Angiography examination, at 1-year follow-up and at final follow-up to a maximum of 4 years
Rate of follow-up Invasive Coronary Angiographies and Percutaneous Coronary Interventions more than 2 months after initial Computed Tomography/Invasive Coronary Angiography and up to first and last follow-up	Rate of follow-up Invasive Coronary Angiographies and Percutaneous Coronary Interventions more than 2 months after initial Computed Tomography/Invasive Coronary Angiography and up to first and last follow-up	during the Invasive Coronary Angiography examination, at 1-year follow-up and at final follow-up to a maximum of 4 years
Correlation of the number of projections for the right and left coronary artery with effective dose of Invasive Coronary Angiography	Correlation of the number of projections for the right and left coronary artery with effective dose of Invasive Coronary Angiography	during the Invasive Coronary Angiography examination, at 1-year follow-up and at final follow-up to a maximum of 4 years
Rates of left ventriculography performed	Rates of left ventriculography performed	during the Invasive Coronary Angiography examination, at 1-year follow-up and at final follow-up to a maximum of 4 years
Rates of planned cross-over from Computed Tomography to Invasive Coronary Angiography	Rates of planned cross-over from CT to ICA after positive findings in CT within 2 month past initial procedure in accordance to management flow chart.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Comparison of cross-over patients (from Computed Tomography to Invasive Coronary Angiography) to non-cross-over-patients	Comparison of cross-over patients (from Computed Tomography to Invasive Coronary Angiography) to non-cross-over-patients.	up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation of Computed Tomography Angiography and/or Invasive Coronary Angiography with the results of imaging ischemia tests	Composite outcome: Correlation of CTA and/or ICA results with the results of imaging ischemia tests (stress echo, stress Single Photon Emission Computed Tomography (SPECT), stress Positron Emission Tomography (PET), MRI & stress MRI).	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation between imaging ischemia tests and invasive Fractional Flow Reserve if done	Correlation between imaging ischemia tests and invasive Fractional Flow Reserve if done.	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Rates of imaging ischemia tests recommended	Rates of imaging ischemia tests recommended	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Comparison of diagnostic accuracy of imaging ischemia tests	Comparison of diagnostic accuracy of imaging ischemia tests (stress echocardiography, SPECT, stress MRI, and PET) for the detection of CTA- or ICA-defined CAD (up to 48h after final procedure related to the randomised test).	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Comparison of imaging ischemia results with Computed Tomography Angiography and Invasive Coronary Angiography results for prediction of Major and Minor Cardiac Adverse Events	Comparison of imaging ischemia results with Computed Tomography Angiography and Invasive Coronary Angiography results for prediction of Major and Minor Cardiac Adverse Events.	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation between imaging ischemia results and coronary stenosis as well as plaque composition and characterisation findings by Computed Tomography Angiography	Correlation between imaging ischemia results and coronary stenosis as well as plaque composition and characterisation findings by Computed Tomography Angiography.	at baseline, up to 48h after the final procedure related to the test randomised to, at 1-year follow-up and final follow-up to a maximum of 4 years
Rate of revascularisations recommended and performed after Computed Tomography Angiography and positive or negative imaging ischemia tests in comparison to Invasive Coronary Angiography arm within two month after the initial test	13.2.1 Rate of PCI / CABG recommended and performed after CTA and positive or negative imaging ischemia tests in comparison to the ICA arm within two month after the initial test.	at baseline, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation of the results of study- Computed Tomography Angiography, recommended imaging ischemia test and Invasive Coronary Angiography in patients with respective study course	Correlation of the results of study- CTA, recommended imaging ischemia test and ICA in patients with respective study course	at baseline, at 1-year follow-up and final follow-up to a maximum of 4 years
Occurrence of procedural events in imaging ischemia testing	Occurrence of procedural events in imaging ischemia testing.	at baseline, at 1-year follow-up and final follow-up to a maximum of 4 years
Correlation of intensity and reduction of angina pectoris	Correlation of intensity and reduction of Angina Pectoris (measured on a 0-10 scale, baseline, first and final follow up, max 4 years) with positive, unequivocal, and negative imaging ischemia test results in patients in both study arms; sub-study in patients with imaging ischemia follow-up examinations with an analysis of the correlation between changes in angina intensity and ischemia extent.	at baseline, at 1-year follow-up and final follow-up to a maximum of 4 years
Analysis of patient acceptance ("preference questionnaire") of Computed Tomography Angiography and Invasive Coronary Angiography	Analysis of patient acceptance ("preference questionnaire") of CTA and ICA (and in those patients, who received both, which one was the preferred) as well as in the following subgroups: gender, patients without significant stenosis seen on the initial test randomised to, patients with significant stenosis seen on CTA and a) ICA not recommended or done e.g., because of imaging ischemia results or b) ICA done.	at baseline, up to 48h after hours after the final procedure related to the test randomized to, 1-year follow-up and final follow-up to a max of 4 years
Patient acceptance of informed consent, preparation and procedural aspects of the test performed	Patient acceptance of informed consent, preparation, procedural aspects of the tests performed including an assessment of maximum pain during procedures measured using a pain scale and patient acceptance of the management recommendations in the two groups.	at baseline, up to 48h after hours after the final procedure related to the test randomized to, 1-year follow-up and final follow-up to a max of 4 years
Effective radiation dose for Computed Tomography Angiography and Invasive Coronary Angiography	Effective radiation dose (measures as dose length product and dose area product during CT [for coronary artery calcium score (CACS) and CTA] and ICA, respectively) used for CT and ICA and cumulative radiation dose in the two arms at different time points.	up to 48h after the final procedure related to the test randomised, at 1-year follow-up and final follow up to a max of 4 years
Reduction of radiation exposure by using coronary artery calcium score information	Reduction of radiation exposure by using CACS information about the coronary artery position along the Z-axis to reduce the Z-axis coverage of the subsequent CTA according to the 10 Steps Guide to Success in Cardiac CT.	up to 48h after the final procedure related to the test randomised, at 1-year follow-up and final follow up to a max of 4 years
Comparison of radiation dose in Invasive Coronary Angiography and Computed Tomography Angiography: pilot study versus non-study patients	Comparison of radiation dose in ICA and CT: pilot study versus non-study patients	during Computed Tomography Angiography and Invasive Coronary Angiography Examination
Validation of the coronary artery disease DISCHARGE and COME-CCT pre-test probability calculators	Validation of the coronary artery disease DISCHARGE and COME-CCT pre-test probability calculators and comparison with other calculators (Diamond and Forrester, DiCAD, Duke clinical score) versus the reference standards (CTA or ICA) in the pilot study of DISCHARGE and the randomised trial.	at 1-year follow-up and final follow-up to a maximum of 4 years
Comparison of the ability of the DISCHARGE and COME-CCT pre-test probability calculators to predict Coronary Artery Disease indifferent genders	Comparison of the ability of the DISCHARGE and COME-CCT pre-test probability calculators to predict CAD in men and women equally well in comparison to previous calculators.	at 1-year follow-up and final follow-up to a maximum of 4 years
Ability of the DISCHARGE and COME-CCT pre-test probability calculators to predict Coronary Artery Disease	Ability of the DISCHARGE and COME-CCT pre-test probability calculators to predict CAD in patients without or with coronary artery calcium on CT using CTA or ICA as the reference standard in comparison to previous calculators.	at 1-year follow-up and final follow-up to a maximum of 4 years
Potential advantage of the DISCHARGE and COME-CCT calculators	Potential advantage of the DISCHARGE and COME-CCT calculators in combination with the NIH chest discomfort guidelines to triage patients most effectively based on pretest probability in comparison to the DISCHARGE approach of CT including calcium scoring and CTA for management decision making about risk factor modification and revascularisation, respectively.	at 1-year follow-up and final follow-up to a maximum of 4 years
Predictive value of the DISCHARGE calculator in patients who could not be included in the trial due to their very low pre-test probability (<10%)	Predictive value of the DISCHARGE calculator in patients with a very low pre-test probability (<10%) who could not be randomised but were sent with an indication for ICA that these patients, who are in a screening log of the study, actually have no CAD on ICA.	at 1-year follow-up and final follow-up to a max of 4 years
Predictive value of the DISCHARGE calculator	Predictive value of the DISCHARGE calculator in patients with a high pre-test probability (>60%) who could not be randomised but were sent with an indication for ICA that these patients, who are in a screening log of the study, actually have a high risk of CAD on subsequent ICA.	at 1-year follow-up and final follow-up to a max of 4 years
Development and validation of a novel pre-test probability calculator	Composite outcome: Development and validation of a novel pre-test probability calculator based on age, gender, symptoms, and cardiac risk factors and/or exercise ECG or imaging ischemia results of patients in DISCHARGE with CT and/or ICA results being the reference standard for the definition of CAD for this novel calculator; comparison of this novel calculator with the simple DISCHARGE pre-test probability calculator.	at 1-year follow-up and final follow-up to a maximum of 4 years
Ability of the DISCHARGE and COME-CCT calculators to predict Major and Minor Adverse Cardiac Events	Ability of the DISCHARGE and COME-CCT (Collaborative Meta-analysis in Cardiac CT) calculators (used in the study and developed based on the study results) to predict MACE and MICE at both follow-up will be analysed.	at 1-year follow-up and final follow-up to a maximum of 4 years
Cost-Effectiveness Analysis	In addition to the costs of CTA and ICA, we assess costs induced by complications caused by these diagnostic procedures. Those costs split up into costs for additional diagnostics and additional treatments necessary due to the occurrence of major cardiovascular adverse events. Therefore, number, type and severity of adverse events, caused by CTA and ICA will be evaluated as well as the type of treatment and if the treatment is conducted in an ambulant setting or requires hospitalisation.	at 1-year follow-up and final follow-up to a max of 4 years
Cost-Utility Analysis	Comparison of the costs of an additional quality adjusted life year (QALY) gained by a correct diagnosis gained by using CTA or ICA.	at 1-year follow-up and final follow-up to a max of 4 years
Comparison of cost-effectiveness analysis and cost-utility analysis in different European countries	All analyses including costs will be conducted separately for each country with a study center to enable us to conduct comparative analyses on an international level.	at 1-year follow-up and final follow-up to a max of 4 years
Average days off work per patient by clinical site during follow up	Adverse events might lead to sick leave in patients, which is an important cost factor from the societal perspective. There will be an assessment of differences in sick leave in patients by clinical site.	at 1-year follow-up and final follow-up to a max of 4 years
Days in hospital per patient by clinical site during follow up	Adverse events might lead to hospitalisation in patients. In addition to days off work, this is an important cost factor from the societal perspective. There will be an assessment of differences in hospitalisation in patients by clinical site.	at 1-year follow-up and final follow-up to a max of 4 years
Additional diagnostic tests during follow-up by clinical site	Differences in adverse events might lead to a different use of diagnostic tests during the follow-up phase. Therefore, data about cost-effective differences in examinations, not being mandatory according to the study protocol, will be collected.	at 1-year follow-up and final follow-up to a max of 4 years
Additional treatments during follow-up by clinical site	Differences in adverse events might lead to a different necessity of treatments during the follow-up phase. Therefore, data about cost-effective differences in treatments, not mandatory by study protocol, will be collected.	at 1-year follow-up and final follow-up to a max of 4 years
Pragmatic assessment of staff involvement time and material use - completion of questionnaires	A pragmatic Case Report Form (CRF) for the assessment of staff involvement time and use of material was developed for the pilot study. The completion of questionnaires in different clinical sites will be assessed to evaluate this approach.	up to a maximum of 2 years after completion of pilot study at all sites
Differences in staff involvement time for Computed Tomography Angiography and Invasive Coronary Angiography in different clinical sites	Differences in staff involvement time in different clinical sites will be assessed. Staff involvement time is one of the major cost drivers in health care systems.	up to a maximum of 2 years after completion of pilot study at all sites
Differences in consumption of materials in different clinical sites	Different consumption of materials in different clinical sites will be assessed. Therefore we will use standardised prices for inter-site comparisons.	up to a maximum of 2 years after completion of pilot study at all sites
Comparison of population of pilot study between the different European clinical sites	The pilot study is not a prospective randomised trial. Inclusion of patients with a pretest-likelihood greater than 60% was allowed due to retrospective calculation of pretest likelihood. Thus, the population in the pilot study differs from the population being included in the DISCHARGE main trial. As cost-effectiveness data will be calculated using data from the pilot study, controlling for age, gender, pretest-likelihood, and quality of live related parameters and others is essential. The prevalence of coronary artery disease will be assessed by site.	up to a maximum of 2 years after completion of pilot study at all sites
Correlation of previous cardiac examination results of patients included in the pilot study with result of Computed Tomography Angiography and Invasive Coronary Angiography	Previous cardiac examination results will be assessed in the pilot study, reflecting the routinely performed tests before referral to Computed Tomography Angiography and Invasive Coronary Angiography. The correlation of these previous tests with the CTA or ICA results will be analysed.	up to a maximum of 2 years after completion of pilot study at all sites
Comparison of hospitalisation after Invasive Coronary Angiography in different European clinical sites	Due to differences in clinical practice and recommendations throughout Europe, patients may be hospitalized after Invasive Coronary Angiography. Analysis will be conducted to assess this cost factor.	up to a maximum of 2 years after completion of pilot study at all sites
Assessment of non-diagnostic segments in Computed Tomography Angiography and Invasive Coronary Angiography in the pilot study	Non-diagnostic segments can occur in Computed Tomography Angiography and Invasive Coronary Angiography. This might lead to subsequent examinations, thus indicating an important cost factor.	up to a maximum of 2 years after completion of pilot study at all sites
Assessment of major cardiovascular adverse events in the pilot study	Occurrence of major cardiovascular adverse events within 48 hours after examination will be analyzed. As major cardiovascular adverse events may lead to subsequent examinations they represent a major cost factor.	up to a maximum of 2 years after completion of pilot study at all sites
Health related Quality of Life and Lifestyle	Composite outcome: Group (CTA vs ICA) differences in health-related QoL instruments (SF-12 self-rated health item, SF-12 physical component summary score, EuroQol 5d-3L and Hospital Anxiety and Depression Scale). Hypothesis: There will be no group differences in QoL at 1 year and final follow-up. We will analyse sociodemographic, lifestyle and clinical predictors of changes in QoL (SF-12 physical component and VAS) between baseline and 1 year / final follow-up, separately for men and women. Important clinical predictors include significant CAD findings during the course of the study, changes in chest pain severity (Angina class), occurrence of MICE / MACE as well as baseline risk factor status (BMI, diabetes, smoking, physical inactivity, excessive alcohol intake).	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Acceptance of time trade-off question in the pilot study	Acceptance of time trade-off question in the pilot study	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Comparison of the health instruments	Comparison of the QoL questionnaires used in the pilot and in the main study (SF-12, EuroQoL 5d-3L, Hospital Anxiety and Depression Scale, and the MacNew).	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences regarding all aspects of medical history	Gender differences regarding all aspects of medical history will be collected at randomization and follow-up. Data will be analysed in regards to occurrence of MACE and MICE in all genders.	: at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences in radiation exposure and gender	Differences in radiation exposure and gender.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences regarding Quality of Life, lifestyle and socioeconomic status	Differences regarding QoL, lifestyle and socioeconomic status at baseline as well as in regards to changes of these factors seen at the two follow-up time points in the two randomised groups and in male and female patients with and without CAD on testing.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences in examination results	Comparison of the examination results (rate of coronary artery disease, PCI rate adjusted for CAD prevalence, occurrence of adverse events, stress tests used, patient acceptance) in all genders.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences of coronary plaque characteristics determined by Computed Tomography	Gender differences of coronary plaque characteristics determined by CT including parameters like coronary plaque assessment, including calcified, mixed and non-calcified plaques, remodeling index, ring-sign, spotty calcification.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences of myocardial resting blood flow / tissue characteristics determined by Computed Tomography Angiography	Gender differences of myocardial resting blood flow / tissue characteristics determined by cardiac CT using parameters such as regional and global TPR, AD, PI, perfusion defects, myocardial calcification, myocardial fatty infiltration, myocardial thinning.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Diagnostic value of Computed Tomography in men vs women - frequency of true positive findings in patients referred for Invasive Coronary Angiography	Diagnostic value of CT in men vs women - frequency of true positive findings in patients referred for ICA - i.e. frequency of revascularization in patients referred for ICA based on CT with and without ischemia testing, CT findings, Ischemia testing findings, ICA findings and revascularization in patients of the CT group referred to ICA as a consequence of index evaluation, radiation dose.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences of pulmonary findings of Computed Tomography Angiography	Composite outcome: Gender differences of pulmonary findings of cardiac CT a) signs of pulmonary congestion: Ground-Glass Opacification (GGO), Pleural effusions, interlobular transudate high density pulmonary attenuation index b) pulmonary emphysema (with/without CAD), low density pulmonary attenuation index c) Pulmonary embolism (major, minor).	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Gender differences of structural Computed Tomography Angiography findings	Gender differences of structural cardiac CT findings including parameters such as LV-mass, volumes and dimensions of Left Ventricle (LV), Left Atrium (LA), Right Ventricle (RV), Right Atrium (RA) and blood pressure.	at baseline, at 1-year follow-up and final follow-up to a max of 4 years
Analysis of occurrence in Major Adverse Cardiac Events in subgroups	Composite outcome: Analysis of occurrence in MACE as a secondary outcome in following subgroups: Angina classification groups CT plaque characteristic groups: high risk versus other plaques versus no plaques Gender: male versus female Age: occurrence of MACE in patient a) under 45 years, b) between 45 and 65 years and c) over 65 years QoL: patients with significant QoL reductions versus patients with no changes in QoL BMI: Patients with BMI a) under 25, b) between 25 and 30 and c) over 30	at baseline, at 1-year follow-up and final follow up to a max of 4 years
Major Adverse Cardiac Events in different composites	Composite outcome: definition of MACE as a) vascular death or Myocardial Infarction (MI), b) cardiac death or MI.	at baseline, at 1-year follow-up and final follow up to a max of 4 years
Occurrence of Myocardial Infarction and stroke	Occurrence of myocardial infarction and stroke	at baseline, at 1-year follow-up and final follow up to a max of 4 years

Collaborators and Investigators

• Sponsor: Charite University, Berlin, Germany
• Investigators: Principal Investigator: Marc Dewey, Prof. Dr., Charite University, Berlin, Germany

Publications and helpful links

General Publications

• Napp AE, Haase R, Laule M, Schuetz GM, Rief M, Dreger H, Feuchtner G, Friedrich G, Spacek M, Suchanek V, Fuglsang Kofoed K, Engstroem T, Schroeder S, Drosch T, Gutberlet M, Woinke M, Maurovich-Horvat P, Merkely B, Donnelly P, Ball P, Dodd JD, Quinn M, Saba L, Porcu M, Francone M, Mancone M, Erglis A, Zvaigzne L, Jankauskas A, Sakalyte G, Haran T, Ilnicka-Suckiel M, Bettencourt N, Gama-Ribeiro V, Condrea S, Benedek I, Cemerlic Adjic N, Adjic O, Rodriguez-Palomares J, Garcia Del Blanco B, Roditi G, Berry C, Davis G, Thwaite E, Knuuti J, Pietila M, Kepka C, Kruk M, Vidakovic R, Neskovic AN, Diez I, Lecumberri I, Geleijns J, Kubiak C, Strenge-Hesse A, Do TH, Fromel F, Gutierrez-Ibarluzea I, Benguria-Arrate G, Keiding H, Katzer C, Muller-Nordhorn J, Rieckmann N, Walther M, Schlattmann P, Dewey M; DISCHARGE Trial Group. Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial. Eur Radiol. 2017 Jul;27(7):2957-2968. doi: 10.1007/s00330-016-4620-z. Epub 2016 Nov 18.
• Haase R, Dodd JD, Kauczor HU, Kazerooni EA, Dewey M. Developing a lung nodule management protocol specifically for cardiac CT: Methodology in the DISCHARGE trial. Eur J Radiol Open. 2020 Jun 25;7:100235. doi: 10.1016/j.ejro.2020.100235. eCollection 2020.
• Feger S, Ibes P, Napp AE, Lembcke A, Laule M, Dreger H, Bokelmann B, Davis GK, Roditi G, Diez I, Schroder S, Plank F, Maurovich-Horvat P, Vidakovic R, Veselka J, Ilnicka-Suckiel M, Erglis A, Benedek T, Rodriguez-Palomares J, Saba L, Kofoed KF, Gutberlet M, Adic F, Pietila M, Faria R, Vaitiekiene A, Dodd JD, Donnelly P, Francone M, Kepka C, Ruzsics B, Muller-Nordhorn J, Schlattmann P, Dewey M. Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. Eur Radiol. 2021 Mar;31(3):1471-1481. doi: 10.1007/s00330-020-07175-z. Epub 2020 Sep 9.
• Dewey M, Rief M, Martus P, Kendziora B, Feger S, Dreger H, Priem S, Knebel F, Bohm M, Schlattmann P, Hamm B, Schonenberger E, Laule M, Zimmermann E. Evaluation of computed tomography in patients with atypical angina or chest pain clinically referred for invasive coronary angiography: randomised controlled trial. BMJ. 2016 Oct 24;355:i5441. doi: 10.1136/bmj.i5441. Erratum In: BMJ. 2016 Nov 29;355:i6420. doi: 10.1136/bmj.i6420.
• De Rubeis G, Napp AE, Schlattmann P, Geleijns J, Laule M, Dreger H, Kofoed K, Sorgaard M, Engstrom T, Tilsted HH, Boi A, Porcu M, Cossa S, Rodriguez-Palomares JF, Xavier Valente F, Roque A, Feuchtner G, Plank F, Stechovsky C, Adla T, Schroeder S, Zelesny T, Gutberlet M, Woinke M, Karolyi M, Karady J, Donnelly P, Ball P, Dodd J, Hensey M, Mancone M, Ceccacci A, Berzina M, Zvaigzne L, Sakalyte G, Basevicius A, Ilnicka-Suckiel M, Kusmierz D, Faria R, Gama-Ribeiro V, Benedek I, Benedek T, Adjic F, Cankovic M, Berry C, Delles C, Thwaite E, Davis G, Knuuti J, Pietila M, Kepka C, Kruk M, Vidakovic R, Neskovic AN, Lecumberri I, Diez Gonzales I, Ruzsics B, Fisher M, Dewey M, Francone M; DISCHARGE Trial Group. Pilot study of the multicentre DISCHARGE Trial: image quality and protocol adherence results of computed tomography and invasive coronary angiography. Eur Radiol. 2020 Apr;30(4):1997-2009. doi: 10.1007/s00330-019-06522-z. Epub 2019 Dec 16. Erratum In: Eur Radiol. 2020 Sep;30(9):5223-5225. doi: 10.1007/s00330-020-06820-x.
• Rieckmann N, Neumann K, Feger S, Ibes P, Napp A, Preuss D, Dreger H, Feuchtner G, Plank F, Suchanek V, Veselka J, Engstrom T, Kofoed KF, Schroder S, Zelesny T, Gutberlet M, Woinke M, Maurovich-Horvat P, Merkely B, Donnelly P, Ball P, Dodd JD, Hensey M, Loi B, Saba L, Francone M, Mancone M, Berzina M, Erglis A, Vaitiekiene A, Zajanckauskiene L, Haran T, Suckiel MI, Faria R, Gama-Ribeiro V, Benedek I, Rodean I, Adjic F, Cemerlic Adjic N, Rodriguez-Palomares J, Garcia Del Blanco B, Brooksbank K, Collison D, Davis G, Thwaite E, Knuuti J, Saraste A, Kepka C, Kruk M, Benedek T, Ratiu M, Neskovic AN, Vidakovic R, Diez I, Lecumberri I, Fisher M, Ruzsics B, Hollingworth W, Gutierrez-Ibarluzea I, Dewey M, Muller-Nordhorn J. Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health Qual Life Outcomes. 2020 May 14;18(1):140. doi: 10.1186/s12955-020-01312-4. Erratum In: Health Qual Life Outcomes. 2020 Jun 29;18(1):205. doi: 10.1186/s12955-020-01443-8.
• DISCHARGE Trial Group; Kofoed KF, Bosserdt M, Maurovich-Horvat P, Rieckmann N, Benedek T, Donnelly P, Rodriguez-Palomares J, Erglis A, Stechovsky C, Sakalyte G, Adic F, Gutberlet M, Dodd JD, Diez I, Davis G, Zimmermann E, Kepka C, Vidakovic R, Francone M, Ilnicka-Suckiel M, Plank F, Knuuti J, Faria R, Schroder S, Berry C, Saba L, Ruzsics B, Kubiak C, Hansen KS, Muller-Nordhorn J, Merkely B, Jorgensen TS, Benedek I, Orr C, Valente FX, Zvaigzne L, Suchanek V, Zajanckauskiene L, Cankovic M, Woinke M, Keane S, Lecumberri I, Thwaite E, Laule M, Kruk M, Neskovic AN, Mancone M, Kusmierz D, Feuchtner G, Pietila M, Ribeiro VG, Drosch T, Delles C, Loi B, Fisher M, Szilveszter B, Sigvardsen PE, Ratiu M, Kelly S, Garcia Del Blanco B, Rubio A, Drobni ZD, Kragelund C, Rodean I, Regan S, Calabria HC, Boussoussou M, Engstrom T, Hodas R, Napp AE, Haase R, Feger S, Mohamed MMA, Serna-Higuita LM, Neumann K, Dreger H, Rief M, Wieske V, Estrella M, Martus P, Dewey M. Comparative effectiveness of initial computed tomography and invasive coronary angiography in women and men with stable chest pain and suspected coronary artery disease: multicentre randomised trial. BMJ. 2022 Oct 19;379:e071133. doi: 10.1136/bmj-2022-071133.
• DISCHARGE Trial Group; Maurovich-Horvat P, Bosserdt M, Kofoed KF, Rieckmann N, Benedek T, Donnelly P, Rodriguez-Palomares J, Erglis A, Stechovsky C, Sakalyte G, Cemerlic Adic N, Gutberlet M, Dodd JD, Diez I, Davis G, Zimmermann E, Kepka C, Vidakovic R, Francone M, Ilnicka-Suckiel M, Plank F, Knuuti J, Faria R, Schroder S, Berry C, Saba L, Ruzsics B, Kubiak C, Gutierrez-Ibarluzea I, Schultz Hansen K, Muller-Nordhorn J, Merkely B, Knudsen AD, Benedek I, Orr C, Xavier Valente F, Zvaigzne L, Suchanek V, Zajanckauskiene L, Adic F, Woinke M, Hensey M, Lecumberri I, Thwaite E, Laule M, Kruk M, Neskovic AN, Mancone M, Kusmierz D, Feuchtner G, Pietila M, Gama Ribeiro V, Drosch T, Delles C, Matta G, Fisher M, Szilveszter B, Larsen L, Ratiu M, Kelly S, Garcia Del Blanco B, Rubio A, Drobni ZD, Jurlander B, Rodean I, Regan S, Cuellar Calabria H, Boussoussou M, Engstrom T, Hodas R, Napp AE, Haase R, Feger S, Serna-Higuita LM, Neumann K, Dreger H, Rief M, Wieske V, Estrella M, Martus P, Dewey M. CT or Invasive Coronary Angiography in Stable Chest Pain. N Engl J Med. 2022 Apr 28;386(17):1591-1602. doi: 10.1056/NEJMoa2200963. Epub 2022 Mar 4.

Helpful Links

• Project homepage
• European Commission Project homepage

Study record dates

Study Major Dates

• Study Start (Actual): October 3, 2015
• Primary Completion (Actual): March 1, 2022
• Study Completion (Actual): March 1, 2022

Study Registration Dates

• First Submitted: January 15, 2015
• First Submitted That Met QC Criteria: March 25, 2015
• First Posted (Estimated): March 27, 2015

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 11, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Keywords: coronary artery disease; angiography; invasive coronary angiography; stable chest pain; intermediate pretest probability; pragmatic randomised controlled trial; coronary computed tomography
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Vascular Diseases; Cardiovascular Diseases; Heart Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Chest Pain
• Other Study ID Numbers: EA1/294/13; EC-GA 603266 (Other Grant/Funding Number: European Commission); Z 5 - 22462/2 - 2014-001 (Other Identifier: German Federal Office for Radiation Protection)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED